Literature DB >> 7000101

Haemodynamic changes induced by prostacyclin in man.

J Szczeklik, A Szczeklik, R Nizankowski.   

Abstract

Intra-arterial or intravenous infusion of prostacyclin at three dose levels (2, 5, and 10 ng/kg per min) in 10 subjects without evidence of coronary heart disease or cardiac failure, led to a distinct fall in peripheral and total pulmonary vascular resistances. This was accompanied by a drop in intra-arterial blood pressure, and the acceleration of heart rate. Stroke volume, cardiac output, mean right atrial pressure, and left ventricular end-diastolic pressure showed no significant changes. Except for sporadic headache no side effects occurred. Prostacyclin appears to act predominantly on resistance vessels. The haemodynamic effects produced by prostacyclin in man might be of clinical interest in the treatment of conditions associated with a significant rise in vascular resistance.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7000101      PMCID: PMC482394          DOI: 10.1136/hrt.44.3.254

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  15 in total

1.  Inhibition of prostacyclin formation by lipid peroxides in the arterial wall: hypothetical step in development of atherosclerosis.

Authors:  R J Gryglewski; A Szczeklik
Journal:  Mater Med Pol       Date:  1978 Oct-Dec

2.  Prostaglandins in the cardiovascular system in man. A biochemical and physiological study.

Authors:  J Nowak
Journal:  Acta Physiol Scand Suppl       Date:  1979

3.  Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men.

Authors:  A Szczeklik; R J Gryglewski; R Nizankowski; J Musiał; R Pietoń; J Mruk
Journal:  Pharmacol Res Commun       Date:  1978-06

4.  Systolic time intervals in heart failure in man.

Authors:  A M Weissler; W S Harris; C D Schoenfeld
Journal:  Circulation       Date:  1968-02       Impact factor: 29.690

5.  Clinical evaluation of left ventricular pressures in myocardial infarction.

Authors:  W W Parmley; G Diamond; H Tomoda; J S Forrester; H J Swan
Journal:  Circulation       Date:  1972-02       Impact factor: 29.690

Review 6.  Vasodilator therapy of pump failure complicating acute myocardial infarction.

Authors:  B M Massie; K Chatterjee
Journal:  Med Clin North Am       Date:  1979-01       Impact factor: 5.456

7.  Pulmonary and systemic vasodilator effects of the newly discovered prostaglandin, PGI2.

Authors:  P J Kadowitz; B M Chapnick; L P Feigen; A L Hyman; P K Nelson; E W Spannhake
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1978-09

8.  Effects of prostaglandin E1 on pulmonary circulation in patients with pulmonary hypertension.

Authors:  J Szczeklik; J S Dubiel; M Mysik; Z Pyzik; R Krol; T Horzela
Journal:  Br Heart J       Date:  1978-12

9.  Pulmonary and systemic vascular effects of exogenous prostaglandin I2 in fetal lambs.

Authors:  C W Leffler; J R Hessler
Journal:  Eur J Pharmacol       Date:  1979-02-15       Impact factor: 4.432

10.  Successful therapy of advanced arteriosclerosis obliterans with prostacyclin.

Authors:  A Szczeklik; R Nizankowski; S Skawinski; J Szczeklik; P Gluszko; R J Gryglewski
Journal:  Lancet       Date:  1979-05-26       Impact factor: 79.321

View more
  13 in total

Review 1.  Prostaglandins and the lung.

Authors:  S P Hanley
Journal:  Lung       Date:  1986       Impact factor: 2.584

2.  Arbaprostil (15(R)-15-methyl PGE2): lack of effect on theophylline metabolism.

Authors:  S B Reele; A Euler; J McEvers; C Metzler
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

3.  Sympathetic and cardiovascular responses to glossopharyngeal insufflation in trained apnea divers.

Authors:  Karsten Heusser; Gordan Dzamonja; Toni Breskovic; Craig D Steinback; André Diedrich; Jens Tank; Jens Jordan; Zeljko Dujic
Journal:  J Appl Physiol (1985)       Date:  2010-09-23

4.  The cardiovascular and platelet actions of 9 beta-methyl carbacyclin (ciprostene), a chemically stable analogue of prostacyclin, in the dog and monkey.

Authors:  G Allan; M J Follenfant; P Lidbury; P L Oliver; B J Whittle
Journal:  Br J Pharmacol       Date:  1985-06       Impact factor: 8.739

5.  The cardiovascular and platelet effects of epoprostenol (prostacyclin, PGI2) are unaffected by beta-adrenoceptor blockade in man.

Authors:  S Hassan; H Pickles; A Fish; C Burke; S Warrington; J O'Grady
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

6.  Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension.

Authors:  T W Higenbottam; D Spiegelhalter; J P Scott; V Fuster; A T Dinh-Xuan; N Caine; J Wallwork
Journal:  Br Heart J       Date:  1993-10

7.  Comparison between prostaglandin E1 and epoprostenol (prostacyclin) in infants after heart surgery.

Authors:  J Kermode; W Butt; F Shann
Journal:  Br Heart J       Date:  1991-08

8.  The effect of intravenous epoprostenol (prostacyclin, PGI2) on cerebral blood flow and cardiac output in man.

Authors:  P J Cook; C G Maidment; P Dandona; R A Hutton; I M James
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

9.  Time course of the effects of epoprostenol on effective pulmonary blood flow in normal volunteers.

Authors:  A Bush; C M Busst; A Millar; N Syrett
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

10.  Effect of epoprostenol (prostacyclin, PGI2) on cerebral blood flow in man.

Authors:  M M Brown; H Pickles
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-11       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.